全文获取类型
收费全文 | 3710篇 |
免费 | 226篇 |
国内免费 | 218篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 18篇 |
妇产科学 | 51篇 |
基础医学 | 501篇 |
口腔科学 | 64篇 |
临床医学 | 319篇 |
内科学 | 408篇 |
皮肤病学 | 31篇 |
神经病学 | 194篇 |
特种医学 | 132篇 |
外科学 | 199篇 |
综合类 | 885篇 |
预防医学 | 335篇 |
眼科学 | 40篇 |
药学 | 390篇 |
5篇 | |
中国医学 | 245篇 |
肿瘤学 | 303篇 |
出版年
2024年 | 3篇 |
2023年 | 114篇 |
2022年 | 230篇 |
2021年 | 144篇 |
2020年 | 210篇 |
2019年 | 121篇 |
2018年 | 100篇 |
2017年 | 164篇 |
2016年 | 156篇 |
2015年 | 215篇 |
2014年 | 375篇 |
2013年 | 218篇 |
2012年 | 287篇 |
2011年 | 329篇 |
2010年 | 245篇 |
2009年 | 202篇 |
2008年 | 101篇 |
2007年 | 157篇 |
2006年 | 136篇 |
2005年 | 85篇 |
2004年 | 63篇 |
2003年 | 95篇 |
2002年 | 49篇 |
2001年 | 36篇 |
2000年 | 30篇 |
1999年 | 55篇 |
1998年 | 43篇 |
1997年 | 40篇 |
1996年 | 42篇 |
1995年 | 19篇 |
1994年 | 22篇 |
1993年 | 11篇 |
1992年 | 14篇 |
1991年 | 11篇 |
1990年 | 14篇 |
1989年 | 10篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1984年 | 1篇 |
排序方式: 共有4154条查询结果,搜索用时 359 毫秒
1.
《HPB : the official journal of the International Hepato Pancreato Biliary Association》2022,24(5):681-690
BackgroundThe American Joint Committee on Cancer (AJCC) made improvements for staging pancreatic neuroendocrine tumors (pNETs) in its 8th Edition; however, multicenter studies were not included.MethodsWe collected multicenter datasets (n = 1,086, between 2004 and 2018) to validate the value of AJCC 8 and other coexisting staging systems through univariate and multivariate analysis for well-differentiated (G1/G2) pNETs.ResultsCompared to other coexisting staging systems, AJCC 7 only included 12 (1.1%) patients with stage III tumors. Patients with European Neuroendocrine Tumor Society (ENETS) stage IIB disease had a higher risk of death than patients with stage IIIA (hazard ratio [HR]: 4.376 vs. 4.322). For the modified ENETS staging system, patients with stage IIB disease had a higher risk of death than patients with stage III (HR: 6.078 vs. 5.341). According to AJCC 8, the proportions of patients with stage I, II, III, and IV were 25.7%, 40.3%, 23.6%, and 10.4%, respectively. As the stage advanced, the median survival time decreased (NA, 144.7, 100.8, 72.0 months, respectively), and the risk of death increased (HR: II = 3.145, III = 5.925, and IV = 8.762).ConclusionThese findings suggest that AJCC 8 had a more reasonable proportional distribution and the risk of death was better correlated with disease stage. 相似文献
2.
Toxicity resulting from off-target effects, beyond acetylcholine esterase inhibition, for the commonly used organophosphate (OP) insecticides chlorpyrifos (CPS) and malathion (MA) was investigated using Saccharomyces cerevisiae and Caenorhabditis elegans model systems. Mitochondrial damage and dysfunction were observed in yeast following exposure to CPS and MA, suggesting this organelle is a major target. In the C. elegans model, the mitochondrial unfolded protein response pathway showed the most robust induction from CPS and MA treatment among stress responses examined. GABAergic neurodegeneration was observed with CPS and MA exposure. Impaired movement observed in C. elegans exposed to CPS and MA may be the result of motor neuron damage. Our analysis suggests that stress from CPS and MA results in mitochondrial dysfunction, with GABAergic neurons sensitized to these effects. These findings may aid in the understanding of toxicity from CPS and MA from high concentration exposure leading to insecticide poisoning. 相似文献
3.
4.
5.
Cadmium is a toxic metal that can damage the brain and other organs. This study aimed to explore the protective effects of Potentilla anserine L. polysaccharide (PAP) against CdCl2-induced neurotoxicity in N2a and SH-SY5Y cells and in the cerebral cortex of BALB/c mice. In addition, we aimed to identify the potential mechanisms underlying these protective effects. Relative to CdCl2 treatment alone, pretreatment with PAP prevented the reduction in cell viability evoked by CdCl2, decreased rates of apoptosis, promoted calcium homeostasis, decreased ROS accumulation, increased mitochondrial membrane potential, inhibited cytochrome C and AIF release, and prevented the cleavage of caspase-3 and PARP. In addition, PAP significantly decreased the CdCl2-induced phosphorylation of CaMKII, Akt, and mTOR. In conclusion, PAP represents a potential therapeutic agent for the treatment of Cd-induced neurotoxicity, functioning in part via attenuating the activation of the mitochondrial apoptosis pathway and the Ca2+-CaMKII-dependent Akt/mTOR pathway. 相似文献
6.
7.
8.
9.
目的 测定不同来源的4种大宗常用中药饮片中黄曲霉毒素(AFB1、AFB2、AFG1和AFG2)的含量,比较不同基质中药饮片中黄曲霉毒素的分布状况。方法 基于免疫亲和柱净化-高效液相色谱分离-荧光检测器(IAC-HPLC-FLD)方法,分析不同产地共75批中药样品。结果 柏子仁、薏苡仁、决明子及党参共计75批中药饮片中,阳性检出:26批柏子仁(AFs 1.22-46.67 μg·kg-1,AFB1 1.22-31.40 μg·kg-1)、4批薏苡仁(AFs 1.97-41.13 μg·kg-1,AFB1 1.97-36.40 μg·kg-1)、1批决明子(AFs 13.65 μg·kg-1,AFB1 12.60 μg·kg-1),阳性率41%,超标率15%。阳性样品经 LC-MS/MS确证,排除假阳性。4种大宗常用中药饮片柏子仁、薏苡仁、决明子、党参中黄曲霉毒素的污染水平依次降低,阳性检出率分别为77%、29%、7%、0%,表明中药材中黄曲霉毒素的污染状况与药材基质密切相关。结论 针对易污染AFs的中药品种,需进一步加强其污染状况的全面检测分析,为黄曲霉毒素的有效防控以及完善中药的质量标准提供科学依据,从而保障中药用药安全。 相似文献
10.
《Journal of thoracic oncology》2020,15(1):91-100
IntroductionClinical studies have shown that a combination of a tyrosine kinase inhibitor (TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor (EGFR) TKI in NSCLC. Previously, pemetrexed+gefintib (P+G) had improved progression-free survival (PFS) compared with gefitinib. We present OS, updated PFS, biomarker analysis, and safety of P+G versus gefitinib.MethodsThis was a phase 2, multicenter, randomized study conducted in East Asian patients with advanced nonsquamous NSCLC with EGFR mutations. Patients were randomized (2:1) to receive P+G (500 mg/m2 intravenously 3-weekly + 250 mg/day orally) or gefitinib.ResultsIn total, 191 patients (P+G, n=126; gefitinib, n=65) comprised the intent-to-treat and safety populations. Median OS was 43.4 months in P+G versus 36.8 months in gefitinib arm; adjusted HR 0.77 (95% CI, 0.5-1.2); one-sided P=0.105. Median PFS was significantly longer in the P+G (16.2 months) versus gefitinib arm (11.1 months); adjusted HR 0.67 (95% CI, 0.5-0.9); one-sided P=0.009. In the P+G and gefitinib arms, median PFS was 22.6 and 11.0 months, respectively, in patients with low thymidylate synthase (TS) expression, and 12.6 and 9.9 months, respectively, in patients with high TS expression. Common second-line post-discontinuation systemic therapies were EGFR-TKIs and chemotherapy. Most patients experienced at least one adverse event.ConclusionsAddition of pemetrexed to EGFR TKI gefitinib resulted in significantly improved PFS and numerically longer OS compared with gefitinib in treatment-naïve patients with EGFR-mutated advanced nonsquamous NSCLC. Low TS expression appeared to be a good predictor for treatment outcomes. 相似文献